Jeffrey Bacon, MD
Critical Care Medicine · Reno, NVNPI 1215910757
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,099 of the $4,674 with a category attached, or 66.3%. 28 manufacturers reported payments, led by GSK at 35.1% of the total. Reporting peaked in 2019 at $1,697 and has fallen 74.1% since, to $440 in 2025. Among critical care medicine clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 212 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Medtronic$1K
- Boston Scientific$576
- AstraZeneca$209
- Johnson & Johnson$197
- AbbVie$189
- plus $856 from 22 others
What the payments were for
- Travel & lodging$1,41530%
- Food & beverage$3,09966%
- Education$1603%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 118 | $1,639 |
| Medtronic | 12 | $1,006 |
| Boston Scientific | 5 | $576 |
| AstraZeneca | 8 | $209 |
| Johnson & Johnson | 6 | $197 |
| AbbVie(2 entities) | 18 | $189 |
| Boehringer Ingelheim | 8 | $162 |
| Harmony Biosciences LLC | 1 | $100 |
| Sunovion Pharmaceuticals Inc. | 6 | $61 |
| Genentech USA, Inc. | 4 | $61 |
| Mallinckrodt Hospital Products Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Philips North America LLC | 2 | $42 |
| Pulmonx Corporation | 2 | $39 |
| Electromed, Inc. | 4 | $36 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Astellas Pharma US Inc | 1 | $30 |
| Lilly USA, LLC | 1 | $28 |
| Insmed, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $17 |
| Baxter Healthcare | 1 | $16 |
| Veran Medical Technologies, Inc. | 1 | $8 |
| Ceribell, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUMISITE$800
- ACQUIRE$480
- XARELTO$125
How this compares
$4,674 in reported general payments places this provider in the 90th percentile of 68 critical care medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 614 | $507,482 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 123 | $67,168 |
| NucalaMepolizumab | 14 | $51,644 |
| Spiriva RespimatTiotropium Bromide | 68 | $46,078 |
| Breo ElliptaFluticasone/Vilanterol | 97 | $44,365 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $25,183 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $23,544 |
| Arnuity ElliptaFluticasone Furoate | 42 | $12,820 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $10,919 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 330 | $9,773 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $5,232 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $5,124 |
| BreynaBudesonide/Formoterol Fumarate | 17 | $4,633 |
| Armodafinil | 12 | $3,750 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $1,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $1,639 | $688,712903 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $162 | $82,181110 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $209 | $28,66758 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 68 critical care medicine providers in Nevada.
Other critical care medicine in Reno
- Farah Madhani-LovelyReno$15K
- Hannah LeitchReno$8K
- Fernando FuentesReno$4K
- Faisal SiddiquiReno$2K
- Joshua BiglerReno$674
- Rudy TedjaReno$587
- Jeremy GondaReno$531
- Jason BlockReno$462
- Joshua JewellReno$399
- Richard MaierReno$312
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.